Dibiopharm co-leads a $10 million Series A round to accelerate the development of genetic drugs through AI

The Debiopharm Innovation Fund is investing strategically in Whitelab Genomics’ mission to make the development of genomic medicine faster and more agile to more efficiently reach cancer patients of the future.

Lausanne, SwitzerlandAnd the September 13, 2022 / CNW / – Debiopharm Innovation Fund, the strategic investment arm of the Swiss biopharmaceutical company Debiopharm (www.Debiopharm.com), today announced their investment in Whitelab Genomics alongside French venture capital firm Omnes Capital, in a $10 million Series A round to advance their mission to accelerate the development of genomic drugs via artificial intelligence (AI)-powered technology. Whitelab Genomics’ computing platform reduces biotherapeutic development time and cost, enabling faster market access and cheaper treatment solutions available to patients in need. Debiopharm’s investment in Whitelabs Genomics contributes to the growth plan of the junior R&D team and US operations. This investment is in line with Debiopharm’s focus on investing in digital health solutions that improve the cancer patient’s journey, transform pharmaceutical research and development, and transform healthcare toward a more patient-centric approach.

Founded in 2019 by David Del BorgoMBA, and Julian CotinoPh.D., along with a team of world-class data scientists specializing in artificial intelligence, computational biologists, molecular biologists, and genetic medicine scientists, the startup offers in silico simulations customized for target discovery, vector and payload design, genotoxicity assessment and defining experimental protocols. for in vitro and in vivo strategies.

We are moving into a time when AI-based technology will play an important role in drug development. With better ways to develop drugs, remove risks, remove risks of any toxicity, and ensure efficacy, we can deliver more personalized drugs to patients – and that’s exactly what Whitelab Genomics has been proven to do,advertiser Tania DaweCEO, Debiopharm Innovation Fund.

The value of using this AI-based platform is the potential acceleration of pre-clinical and multi-phase, helping drug research companies to quickly design payloads and carriers and determine the best experimental protocols for in vitro and in vivo testing,He said Hamza Abdel Hadiinvestment manager at Debiopharm Innovation Fund.

We are very excited to conclude this first round of institutional investment with these renowned investors with deep knowledge of the pharmaceutical environment. With this funding, we can continue to develop our own data sets and algorithms for both payload and carriers, and develop our collaboration with our customers.expressed David Del BorgoCEO and co-founder of Whitelab Genomics.

About Whitelab Genomics

WhiteLab Genomics, based in Paris And the Cambridge (MA) in 2019 by David Del Borgo And the Julian CotinoExperts in the development and marketing of genomics drugs. WhiteLab Genomics aims to revolutionize the development of genetic therapies using public and private data and in-house AI algorithms. Whitelab Genomics supports its clients through the in silico development stages enabling them to rapidly develop vectors and target payloads, saving valuable time needed to give patients access to new gene therapies. In just two years, Whitelab Genomics has convinced leading European and American biotech and pharmaceutical companies to use their solutions for new drug development programs, including RNA, DNA and cell therapies. WhiteLab Genomics also collaborates with world-renowned INSERM and Genethon labs and was selected by Y-Combinator in the Winter 2022 collection. The company has won numerous awards, including the Galien Foundation Nominee for Startups, the Alumni New Venture Fund from Polsky Innovation Center in University of Chicagoand the future 40 from station F.

For more information, please visit the website www.whitelabgx.com

About the Debiopharm Innovation Fund

The Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, provides strategic funding and guidance to companies aspiring to improve the patient journey, and reimagine how clinical trials are conducted, along with companies offering digital platforms that support the latest technology. drug techniques. Since 2017, Debiopharm has invested in 14 digital health companies, usually leading the investment rounds.

For more information, please visit www.debiopharm.com/digital-health/
We are on Twitter. Follow us on DebiopharmNews at http://twitter.com/DebiopharmNews

Contact Debiopharm

bonin dawn
Head of Communications
dawn.bonine@debiopharm.com
Phone: +41 (0) 21321 01 11

Cision

Cision

View original content:https://www.prnewswire.com/news-releases/debiopharm-co-leads-a-10m-usd-series-a-round-to-accelerate-the-development-of-genomic-medicines-through-artuate- Intelligence 301623341.html

SOURCE Debiopharm International SA

Cision

Cision

View original content: http://www.newswire.ca/en/releases/archive/September2022/13/c2270.html

Leave a Comment